Lyka Labs (NSE:LYKALABS) Total Liabilities : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Lyka Labs Total Liabilities?

Lyka Labs's Total Liabilities for the quarter that ended in Dec. 2024 was ₹0 Mil.

Lyka Labs's quarterly Total Liabilities increased from Jun. 2024 (₹0.00 Mil) to Sep. 2024 (₹695.63 Mil) but then declined from Sep. 2024 (₹695.63 Mil) to Dec. 2024 (₹0.00 Mil).

Lyka Labs's annual Total Liabilities declined from Mar. 2022 (₹1,721.23 Mil) to Mar. 2023 (₹1,058.52 Mil) and declined from Mar. 2023 (₹1,058.52 Mil) to Mar. 2024 (₹884.59 Mil).

Lyka Labs Total Liabilities Historical Data

The historical data trend for Lyka Labs's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Total Liabilities Chart

Lyka Labs Annual Data

Trend

Jun14

Jun15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

2,152.80

2,151.05

1,721.23

1,058.52

884.59

Lyka Labs Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															-	884.59	-	695.63	-

Lyka Labs Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lyka Labs's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	376.402	+	(430.843	+	59.121
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	18.222	+	0)
	=	885

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	1567.242	-	682.654
	=	885

Lyka Labs's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	N/A

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	N/A	-	N/A
	=	N/A

Lyka Labs Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyka Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (NSE:LYKALABS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

500259:India

Address

30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036

Website

http://www.lykalabs.com

Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs Headlines

No Headlines